Ultime notizie per OPKO Health (NASDAQ:OPK) Azioni

OPKO Health

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.

OPKO Health Inc

Digital Holdings Inc

OPKO HEALTH ORD

Development Based On ModeX's MSTAR Technology To Prepare For Emerging Viral Threats

Biotech

News

General

ModeX Therapeutics Secures $35M BARDA Supplement For COVID Multispecific Antibodies And $16M For Influenza Program; Total BARDA Awards Now At $110M With Potential To Reach $205M If All Options Are Exercised

Will Support Sales And Marketing Of OPKO Products On Additional E-Commerce Platforms And Social Media Channels; Agreement Includes Exclusive Rights For Japanese Market, One Of The World's Largest E-Commerce Markets With $151B Revenue In 2023

NXPL

NextPlat Secures Four-Year Extension Of OPKO Healthcare E-Commerce Program In China And Expands Program To Japan

HC Wainwright &amp; Co. analyst Yi Chen reiterates OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Buy and maintains $3 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on OPKO Health, Maintains $3 Price Target

ENTX

Entera Bio And OPKO Health Announce PK/PD Results For Oral Oxyntomodulin Peptide Tablet Candidate, Showing Significant Systemic Exposure And Favorable PK Profile In Obesity And Metabolic Disorder Studies; Oral OXM Demonstrates Prolonged Systemic Exposure Comparable To Semaglutide

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and maintains $2.25 price target.

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

During the last three months, 4 analysts shared their evaluations of OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for OPKO Health, revealing an average target of $2.81, a high estimate of $3.00, and a low estimate of $2.25. Highlighting a 9.94% decrease, the current average has fallen from the previous average price target of $3.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1726585238_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive OPKO Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$2.25</td>
<td>$1.50</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$3.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OPKO Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of OPKO Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for OPKO Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of OPKO Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OPK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on OPKO Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into OPKO Health's Background</h2>
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
<h3>Key Indicators: OPKO Health's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: OPKO Health's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -31.36%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: OPKO Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -5.66%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): OPKO Health's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.78%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): OPKO Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.52%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: OPKO Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For OPKO Health

Piper Sandler analyst Edward Tenthoff reiterates OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Overweight and maintains $3 price target.

Piper Sandler Reiterates Overweight on OPKO Health, Maintains $3 Price Target

The acquisition includes&nbsp;BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey, including certain patient service centers (PSCs), customer contracts and operating assets, which currently generate approximately $100 million in annual revenue.

Health Care

Laboratory Corporation Of America Holdings

Labcorp Has Completed The Acquisition Of Select Assets Of And Opko Health's Bioreference Health For $237.5M

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and raises the price target from $1.5 to $2.25.

Barrington Research Maintains Outperform on OPKO Health, Raises Price Target to $2.25

WIIM

OPKO Health shares are trading higher after the company reported better-than-expected Q2 EPS results.

OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.09) by 88.89 percent. The company reported quarterly sales of $182.200 million which missed the analyst consensus estimate of $185.190 million by 1.61 percent. This is a 31.35 percent decrease over sales of $265.400 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

OPKO Health Q2 2024 GAAP EPS $(0.01) Beats $(0.09) Estimate, Sales $182.200M Miss $185.190M Estimate

Opko Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) shares are trading higher Thursday after the company announced a $100 million <a href="https://www.benzinga.com/pressreleases/24/07/g39835824/opko-health-announces-100-million-share-repurchase-program">share repurchase program.</a>
The Details:
Opko said it expects to fund the repurchase program from existing cash and cash equivalents, and future cash flows. The company had approximately 697 million shares outstanding as of June 30, 2024, and the new authorization represents approximately 10.1% of shares outstanding at the current stock price.
Read Next:<a href="https://www.benzinga.com/news/earnings/24/07/39826835/discover-reports-better-than-expected-q2-results-heres-the-details"> Discover Reports Better-Than-Expected Q2 Results: Here&#8217;s The Details</a>
&#8220;We believe OPKO&#8217;s shares are significantly undervalued and offer an attractive investment opportunity. Buying back shares supports our conviction in OPKO&#8217;s strategy as we continue to advance our pipeline in the clinic and streamline our diagnostic segment on a path to profitability,&#8221; said Phillip Frost, M.D., CEO of Opko Health.&nbsp;
Additionally, Opko announced a $250 million non-dilutive note <a href="https://www.benzinga.com/news/24/07/39827620/why-opko-health-shares-are-up-after-hours">purchase agreement </a>with HealthCare Royalty (HCRx) after the market close Wednesday. Opko said the purchase agreement is secured by its profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA, a once-weekly treatment to treat pediatric growth hormone deficiency.
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Opko Health shares are moving on heavy volume and are trading above the stock&#8217;s 50-day moving average of $1.31.&nbsp;
<h2 class="wp-block-heading">Should I Sell My OPK Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Opko Health have decreased by 27.39% in the past year. An investor who bought shares of Opko Health at the beginning of the year would take a loss of $0.03 per share if they sold it today. The stock has risen 24.15% over the past month, meaning an investor who bought shares on June 1 would see a capital gain of $0.12.
Opko Health shares have an all-time high of $5.15, representing 234.55% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Opko Health stock currently has an RSI of 84.21, indicating overbought conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
OPK Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Opko Health shares are up 3.87% at $1.47 at the time of publication Thursday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39827454/what-happened-with-intel-stock-today">What Happened With Intel Stock Today?</a></li>
</ul>
Image: Shutterstock

Movers

Opko Health Stock Is Climbing: What's Going On?

U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday.
Shares of Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) rose during Thursday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39839582/cintas-beats-expectations-with-strong-q4-earnings-sets-ambitious-fy25-revenue-target">quarterly EPS and revenues</a>.
Cintas reported fourth-quarter earnings per share of $3.99, beating the street view of $3.80. The company registered quarterly revenues of $2.471 billion, beating the street view of $2.468 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Cintas shares gained 5.3% to $758.25 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) shares gained 47.6% to $37.29 after the company and Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) jointly announced that Darden will acquire Chuy's Holdings.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) jumped 19% to $2.0407. Amphenol announced plans to acquire mobile networks businesses from CommScope.</li>
<li>ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) shares rose 14.7% to $21.74.</li>
<li>Virtu Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) surged 13.2% to $26.61 after the company reported better-than-expected second-quarter financial results.</li>
<li>D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) shares gained 10.6% to $174.29 after the company reported better-than-expected third-quarter financial results and revised its FY24 guidance. Also, the company authorized a new $4 billion share repurchase.</li>
<li>OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) rose 8.5% to $1.54. The company announced a $100 million share repurchase program.</li>
<li>Canadian Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) surged 8.3% to $17.89.</li>
<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) rose 7.5% to $59.12. HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterated Legend Biotech with a Buy and maintained a $73 price target.</li>
<li>Infosys Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) gained 7.4% to $22.07 as the company reported first-quarter revenue growth of 2.5% in constant currency terms year-on-year to $4.71 billion, beating the analyst consensus estimate of $4.65 billion.</li>
<li>Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) rose 7.4% to $85.29. Root is scheduled to host a conference call to discuss financial results for the second quarter on Wednesday, Aug. 7.</li>
<li>Materialise NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) jumped 7.2% to $5.85. Materialise is expected to release financial results for the second quarter on Wednesday, July 31.</li>
<li>BankUnited, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKU#NYSE">BKU</a>) gained 6.6% to $36.95 after the company reported better-than-expected quarterly financial results.</li>
<li>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) gained 6.5% to $260.95 after the company completed the acquisition of Cupertino Electric.</li>
<li>Meritage Homes Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) rose 6.1% to $201.54.</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) rose 6% to $135.83 in sympathy with D.R. Horton, which reported better-than-expected third-quarter financial results.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) gained 5.2% to $8.76 after the Financial Times reported that the company has discussed plans to split its digital streaming and studio businesses from its legacy television networks.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) gained 4.4% to $35.97.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39837094/jim-cramer-can-bless-general-dynamics-its-great-not-expensive">Jim Cramer &#8216;Can Bless&#8217; General Dynamics: &#8216;It&#8217;s Great, Not Expensive</a>&#8216;</li>
</ul>

Intraday Update

Markets

Trading Ideas

CHUY

COMM

CSIQ

CTAS

INFY

INTC

LEGN

MTLS

ROOT

VIRT

ZIMV

Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday

Opko Health shares are trading higher. The company announced a $100 million share repurchase program.

Buybacks

OPKO Health Announces $100M Share Buyback Program

Piper Sandler analyst Edward Tenthoff maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Overweight and lowers the price target from $5 to $3.

Piper Sandler Maintains Overweight on OPKO Health, Lowers Price Target to $3

Opko Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) shares are trading higher after-hours Wednesday. The company announced it entered into a $250 million non-dilutive note purchase <a href="https://www.benzinga.com/pressreleases/24/07/g39825467/opko-health-and-healthcare-royalty-enter-into-250-million-note-purchase-agreement-secured-by-ngenl">agreement with HealthCare Royalty (HCRx). </a>
The Details: Opko said the purchase agreement is secured by its profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA, a once-weekly treatment to treat pediatric growth hormone deficiency. 
The $250 million note issued under the Note Purchase Agreement bears interest at the 3-month Secured Overnight Financing Rate (SOFR) subject to a 4% per annum floor, plus 7.5% per annum. The note has a final maturity date of July 2044 with the first four years requiring interest-only payments.
Read Next:<a href="https://www.benzinga.com/news/24/07/39796841/lucids-stock-drives-higher-on-2025-model-year-updates-whats-going-on"> Lucid&#8217;s Stock Drives Higher On 2025 Model Year Updates: What&#8217;s Going On?</a>
&#8220;This transaction with HCRx allows OPKO to retain a significant portion of NGENLA&#8217;s profit share payments in the near term and provides upside over the long term. It also permits OPKO to maintain the full benefit of the $100 million of remaining potential milestone payments from Pfizer,&#8221; said Phillip Frost, M.D., CEO of Opko.
&#8220;Additionally, it provides non-dilutive capital and financial flexibility to advance our research and development activities including our multispecific antibody programs, as well as potentially to repurchase shares of our common stock and convertible notes."
OPK Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Opko Health shares are up 7.07% after-hours at $1.52 at the time of publication Wednesday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39805320/what-happened-with-canopy-growth-stock-today">What Happened With Canopy Growth Stock Today?</a></li>
</ul>
Image: Shutterstock

After-Hours Center

Why Opko Health Shares Are Up After-Hours

OPKO Health Enters Into $250M Non-Dilutive Note Purchase Agreement With HealthCare Royalty Secured By Profit Share Payments From Pfizer For NGENLA

New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additional E-Commerce Platforms, in Brick-and-Mortar Retail Locations and Launch In-Country Digital Marketing Programs
COCONUT GROVE, Fla., July 2, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>, NXPLW)))) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that it has expanded its e-commerce development program in China through a new agreement with a leading Chinese healthcare and nutritional products marketing and distribution services partner (the "Marketing Partner"). The Marketing Partner will provide NextPlat with a full range of creative content, brand marketing and product sales and distribution services and support the Company's&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4203578-1&amp;h=995620933&amp;u=https%3A%2F%2Fir.nextplat.com%2Fnews-events%2Fpress-releases%2Fdetail%2F108%2Fnextplats-florida-e-commerce-development-program-to-launch&amp;a=exclusive+joint+e-commerce+development+agreement+with+OPKO+Health+Europe+(%22OPKO%22)">exclusive joint e-commerce development agreement with OPKO Health Europe ("OPKO")</a>, a subsidiary of OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>).

NextPlat Expands E-Commerce Program In China To Include Broad Retail Distribution And Adds Digital/Social Media Marketing Capabilities

Roth MKM says Small-Cap Value reaches key technical support, lists 14 "bullish" stocks

Not Enough To Keep OPKO Health Flying

Opko Health ( ($OPK) ) has shared an update. BioReference Health, an OPKO Health subsidiary, has successfully settled its debts by repaying roughly...

Opko Health Subsidiary Restructures with Strategic Sale and Debt Settlement

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Opko Health (OPK – Research Report). The associated price target remains the...

Opko Health's Strategic Moves and Pipeline Progress Prompt Buy Rating

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Opko Health (OPK – Research Report) today and set a price target of $3.00. The com...

Opko Health (OPK) Receives a Buy from Piper Sandler

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Opko Health (OPK – Research Report), with a price target of ...

Opko Health's Strategic Moves and Financial Prospects Bolster Buy Rating

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Opko Health (OPK – Research Report) and keeping the price target at $3.00. Yi Chen ...

Buy Rating Justified by Opko Health's Promising OXM Candidate and Strategic Asset Sale

OPKO Health Q3 Earnings Preview

Here are the major earnings after the close today

OPKO Health GAAP EPS of $0.03 beats by $0.12, revenue of $173.6M misses by $7.93M

AAOI

AAON

ACHR

ACHV

ADMA

ADPT

AEYE

AFRM

AKAM

ALLO

ALRM

ALTM

AMPL

AMRC

ANET

ARCT

ARLO

ARRY

ASLE

AVUV

DFAS

DFSV

DOCS

DVAX

FIVN

FNKO

FOSL

FYBR

GSBD

GTBIF

HASI

HEAR

INDI

INGN

KNSA

KVYO

LGND

NWSA

OPEN

OUST

PACB

PARA

PBPB

PBYI

PHUN

PINS

PLXS

PODD

PRCH

PTCT

PTMN

QDEL

RCEL

RCMT

RDFN

REZI

RIGL

RIVN

SAND

SCHA

SEMR

SENS

SIGA

SLYV

SPSM

WGSWW

Press Releases

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Management

OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Financing

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024

Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®

OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results

Comments

OPKO Health

Notizie

Ultime notizie per OPKO Health (NASDAQ:OPK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO